CCR6 and primary cutaneous T-cell non-Hodgkin lymphoma: This study by Ito and colleagues provides in vivo evidence that miR-150 is capable of suppressing tumor metastasis and invasion by targeting the chemokine receptor or CCR6, which prevents autocrine signaling in advanced CTCL, particularly IL-22-CCL20-CCR6 signaling [123].